摘要
目的研究骨化三醇治疗血液透析(HD)患者继发性甲状旁腺功能亢进(SHPT)的有效性和安全性。方法选择30例HD患者,血清甲状旁腺激素(iPTH)>300pg/ml,钙磷乘积<4.04mmol2/L2,根据血清iPTH的水平确定骨化三醇的治疗剂量,记录血钙、血磷、钙磷乘积、血iPTH的变化。结果观察治疗6个月后,iPTH水平显著降低(P<0.05),21例患者达到目标范围;治疗过程中有7例出现高磷血症,5例患者出现高钙血症,无1例发生持续性高钙血症,无1例钙磷乘积大于5.65mmol2/L2。结论骨化三醇冲击疗法可有效控制HD患者SHPT,且在SHPT的早期疗效更显著,安全性良好。
Objective To investigate the efficiency and security of calcitriol in treatment of secondary hyperparathyroidism （SHPT） in maintenance hemodialysis（MHD） patients. Methods Thirty MHD patients with intact parathyroid hormone（iPTH） above 300 pg/ml and calcium-phosphorus product under 4.04 mmol2/L2 were enrolled. The dose of calcitriol was given according to the level of iPTH. Serum calcium, phosphorus, calcium-phosphorus product,iPTH were determined. Results After 6 month treatment, the level of iPTH significantly declined（ P 〈 0.05 ）, and reached the targeted range in 21 patients. During treatment, hyperphosphataemia was found in 7 patients, hypercalcemia in 5 patients, and no persistent hypercalcemia appeared. No calcium-phosphorus product above 5.65 mmol2/L2 was observed. Conclusion Calcitriol pulse therapy with reasonably adjusted dosage is effective and safe for SHPT. The effect is better for early SHPT.
出处
《山西医科大学学报》
CAS
2009年第12期1121-1123,共3页
Journal of Shanxi Medical University
